
Altria reported a US$4.1 billion write-down on its Juul Labs investment on Thursday, January 20, another sizable charge as the vaping crisis continues to roil the e-cigarette industry, reported The Wall Street Journal.
The company now values its 35% percent stake in the e-cigarette company at US$4.2 billion, a significant drop from the US$12.8 billion it paid in December 2018. Three months ago, Altria, one of the world’s largest tobacco sellers, devalued its investment in Juul by US$4.5 billion.
Altria, the maker of Marlboro cigarettes, stated its fourth-quarter charge was largely because of the growing number of legal cases pending against Juul, which increased by more than 80% percent since the end of October.
Howard Willard, chief executive of Altria, said that despite “the unexpected challenges” Juul faces, the company had made progress in its noncombustible platform with the IQOS e-cigarette and on nicotine pouches.
Full Content: Wall Street Journal
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
House Budget Bill’s Moratorium on State AI Laws Could Undo A Range of Tech Regs, Critics Say
May 14, 2025 by
CPI
Microsoft Nears EU Antitrust Resolution Over Teams Bundling, Sources Say
May 14, 2025 by
CPI
CMA Investigates Aviva’s £3.6B Acquisition of Direct Line Group
May 14, 2025 by
CPI
Google Urges Texas Judge to Disregard Virginia Antitrust Ruling
May 14, 2025 by
CPI
Anthropic Ordered to Respond After AI Allegedly Fabricates Citation in Legal Filing
May 14, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Healthcare Antitrust
May 14, 2025 by
CPI
Healthcare & Antitrust: What to Expect in the New Trump Administration
May 14, 2025 by
Nana Wilberforce, John W O'Toole & Sarah Pugh
Patent Gaming and Disparagement: Commission Fines Teva For Improperly Protecting Its Blockbuster Medicine
May 14, 2025 by
Blaž Višnar, Boris Andrejaš, Apostolos Baltzopoulos, Rieke Kaup, Laura Nistor & Gianluca Vassallo
Strategic Alliances in the Pharma Sector: An EU Competition Law Perspective
May 14, 2025 by
Christian Ritz & Benedikt Weiss
Monopsony Power in the Hospital Labor Market
May 14, 2025 by
Kevin E. Pflum & Christian Salas